PMDA Updates

Hydrangea macrophylla and a snail

June, 2017

News

1. 2nd Korea-Japan Joint Symposium on Medical Products

On May 11, the 2nd Korea-Japan Joint Symposium on Medical Products was held in Seoul, which was attended by about 300 people from PMDA, Ministry of Health, Labour and Welfare (MHLW), Ministry of Food and Drug Safety (MFDS), National Institue of Food and Drug Safety Evaluation and industries. This symposium was held as part of the cooperation activities as set out in the "Memorandum of Cooperation on Medical Products Regulatory Dialogue and Cooperation Framework" signed between MFDS and MHLW in August 2015. Those who participated in the symposium from PMDA included Mr. Seiichi Inoue, Executive Director; Mr. Naoyuki Yasuda, Office Director, Office of International Programs; and 4 other staff, and from MHLW included Mr. Yoshihiko Sano, Deputy Director, Office of International Regulatory Affairs and other staff. In the symposium, presentations were provided by the regulators of both countries on a regulatory overview and updates, and by the industries on recent trends in the pharmaceutical and medical device industries. Each presentation was followed by active discussion among the participants.

On the following day, May 12, a bilateral meeting was held where regulators of Korea and Japan exchanged views on future regulatory harmonization and cooperation, and developed a framework for future cooperation including establishing working groups.

MHLW's press release is available at the following link.

http://www.mhlw.go.jp/stf/houdou/0000164935.html (in Japanese)

2. 3rd Indonesia-Japan Symposium

On May 17, the 3rd Indonesia-Japan Symposium was held in Jakarta, co-hosted by PMDA, National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan: BPOM), Japan Pharmaceutical Manufacturers Association (JPMA) and Gabungan Perusahaan Farmasi Indonesia (GPFI), and was attended by 205 people from pharmaceutical industries and regulatory agencies in Indonesia and Japan (including 40 Japanese industry representatives). From PMDA, Dr. Tatsuya Kondo, Chief Executive; Mr. Shinobu Uzu, Chief Safety Officer; Dr. Junko Sato, Office Director, Office of International Cooperation; and staff of Office of International Cooperation participated as presenters. From BPOM, Dr. Penny K. Lukito, Head of BPOM and many other staff participated in the symposium. Keynote speeches were delivered by Dr. Kondo and Dr. Lukito. Presentations and discussions were conducted by participants from both countries under the themes of establishing the drug review system, and pharmacovigilance, to share regulatory updates in Indonesia and Japan and to exchange views towards further bilateral cooperation.

Mr. Masahiko Yokota, Chief Advisor, JICA (second from left)
Dra (Doktoranda). Nurma Hidayati, Deputy for Therapeutic Product and Narcotics, Psychotropic, and Addictive Substance Control, BPOM (forth from left)
Dr. Penny K. Lukito, Head of BPOM (seventh from left)
Dr. Tatsuya Kondo, Chief Executive (eighth from left)
Mr. Shinobu Uzu, Chief Safety Officer (fourth from right)
Dr. Junko Sato, Office Director, Office of International Cooperation (third from right)

The details of the 3rd Indonesia-Japan Symposium is available at the following link.

http://www.pmda.go.jp/english/symposia/0101.html

3. PMDA-ATC RMP Seminar 2017 in Jakarta, Indonesia

Mr. Shinobu Uzu (front row, third from left)
Dra. Nurma Hidayati (front row, forth from left)
Dr. Junko Sato (front row, second from right)
Mr. Masahiko Yokota (front row, first from right)

From May 18 to 19, PMDA and Japan International Cooperation Agency (JICA) co-hosted a seminar in Jakarta entitled "PMDA-ATC RMP Seminar 2017 in Jakarta, Indonesia". This seminar was organized at the request of National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan: BPOM) under the theme of Risk Management Plan (RMP), and was participated by 30 regulators from Indonesia. In the seminar, lectures were facilitated by PMDA staff on pharmacovigilance, RMP in particular, in an interactive manner with some questions to participants. Also, many questions were raised by participants in the Q&A session, and active discussions took place.

The details of PMDA-ATC RMP Seminar 2017 in Jakarta, Indonesia is available at the following link.
http://www.pmda.go.jp/english/symposia/0108.html

English translations of review reports

The followings are current information about English version of review reports on PMDA web site.

Pharmaceuticals

http://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html

Brand Name	Generic Name	Posting date
Tracleer (pediatric dispersible tablets)	bosentan hydrate	June 2
Opdivo [Partial Change Approval]	nivolumab (genetical recombination)	June 6

Safety Information

Pharmaceuticals Revisions of PRECAUTIONS, May 30, 2017

- Treprostinil
- Dulaglutide (genetical recombination)
- Bosutinib hydrate
- Pneumococcal vaccine

http://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0005.html

Risk Information which some safety measures might be taken (June 9, 2017)

- Hydroxocobalamin
- Fluconazole
- Fosfluconazole
- Patch test products containing gold (I) sodium thiosulfate
- Loxoprofen sodium hydrate(Cataplasms/Gel Patches)
- Loxoprofen sodium hydrate(Tape)
- Loxoprofen sodium hydrate(Gel)
- Loxoprofen sodium hydrate(Spray)
- Loxoprofen sodium hydrate (dermatologic preparation) (guidance-mandatory drugs)

- Nivolumab (genetical recombination)
- Codeine phosphate hydrate
- Dihydrocodeine phosphate
- Codeine phosphate hydrate/cherry bark extract
- Dihydrocodeine phosphate/dl-methylephedrine hydrochloride/chlorpheniramine maleate
- Dihydrocodeine phosphate/diprophylline/dl-methylephedrine hydrochloride/diphenhydramine salicylate/acetaminophen/bromovalerylurea
- Dihydrocodeine phosphate/platycodon fluidextract/glycyrrhiza extract/plantago extract/peony root extract
- Dihydrocodeine phosphate/ephedrine hydrochloride/ammonium chloride
- Products containing codeine phosphate hydrate or dihydrocodeine phosphate (OTC)
- Tramadol hydrochloride
- Tramadol hydrochloride/acetaminophen

http://www.pmda.go.jp/english/safety/info-services/drugs/risk-communications/0001.html

Events

Conferences/Meetings PMDA hosts or participates in:

Date	Title	Location
July 6-8	CVIT 2017 HBD Town Hall Meeting	Kyoto
July 11-13	8th International Meeting of World Pharmacopoeias	Brasilia
July 31-August 4	PMDA-ATC GMP Inspection Seminar* (*with the support of PIC/S)	Yamaguchi

Reports from overseas

Our officers deliver lively reports of their activities at their stationed overseas authorities.

Workshop about projects related to small-population clinical trials under FP7

The workshop was held at EMA on 29-30 March. FP7 (Seventh Framework Programme) is a research funding programme led by EC, which has been replaced with Horizon 2020 since 2014. The scope of the programme is not limited to pharmaceutical and medical field, but it provides research funds to a variety of fields such as agriculture, energy and space.

Under PF7, the following 3 projects related to small population clinical trials have been implemented since 2013 in order to discuss their study designs and analytical methods:

1) Asterix: Advances in Small Trials dEsign for Regulatory Innovation and eXcellence
2) IDeAl: Integrated DEsign and AnaLysis of clinical trials in small population group trials
3) InSPiRe: Innovative methodology for Small Populations Research

Based on the achievements by each project, stakeholders actively exchanged opinions about such topics as utilization of meta-analysis, extrapolation, setting of appropriate endpoints and use of model & simulation at this workshop.

As these topics are important for not only EU but also Japan and discussed at PMDA in cross-departmental projects such as Orphan Drugs Working Group and Paediatric Drugs Working Group, I would like to pay attention to the activities related to small population clinical trials.

Mr. Hideyuki Kondo
PMDA's International Liaison Officer stationed at EMA in the United Kingdom

---

APEC RHSC Regulatory Science Center of Excellence for Product Quality & Supply Chain Pilot Program

United States Pharmacopeial Convention (USP) was endorsed as a Pilot Training Center of Excellence in the area of Global Supply Chain Integrity by Asia-Pacific Economic Cooperation (APEC), Life Science Innovation Forum (LSIF), Regulatory Harmonization Steering Committee (RHSC). The APEC RHSC Regulatory Science Center of Excellence for Product Quality & Supply Chain Pilot Program was held at the USP headquarters on March 28-31[1), 2)]. Regulators from 14 different APEC economies participated in this program. In the plenary session of this program, the current global state of substandard/falsified medicines, the Supply Chain Toolkit[3)] developed under APEC LSIF, and others were introduced. Also, USP staff gave a presentation on the activities by Promoting the Quality Medicines (PQM) which is one of USP Global Health Programs. USP Global Health Programs are striving to help under-resourced countries combat substandard and counterfeit medicines by building local capacity including systems, trainings, infrastructure, and networks[4)]. The speaker reported these activities produce results such as strengthened quality surveillance, reduction of approval time for key medicines, and improved essential medicines supply security in the countries which have been supported by PQM.

I learned through observing this program that distribution and availability of medicines can be important elements for pharmaceutical quality. I will continuously focus on various trends regarding pharmaceutical quality assurance and regulation in the U.S. including USP.

1) APEC RHSC Regulatory Science Center of Excellence for Product Quality & Supply Chain Pilot Program
http://www.usp.org/securing-medical-product-quality-through-supply-chain
2) Working through APEC Supports Public Health Impact and Sustainability
http://spotlight.usp.org/feature-story-our-impact/working-through-apec-supports-public-health-impact-and-sustainability
3) Supply Chain Security Toolkit
http://www.nifds.go.kr/apec/SupplyChain/APEC_SupplyChainToolkit_170317.pdf
4) USP Global Health Programs
http://www.usp.org/global-health-programs

Dr. Yujiro Kameyama
PMDA's Liaison Officer stationed at USP in the U.S.A

Clinical Rating Scales for Outcome Measures and Patients' Perspective programs at FDA

In clinical trials, clinical rating scales are used to measure the efficacy of drugs, outcomes, and disease conditions. There are two programs relevant to clinical rating scales in FDA, Clinical Outcome Assessment (COA) Qualification Program and Patient-Focused Drug Development (PFDD).

COA Qualification Program[1)] is an effort which reviews outcome measures for clinical trials. COAs include Patient-reported outcome (PRO) measures and Clinician-reported outcome (ClinRO) measures. A guidance of PRO measures by FDA was published in 2009. This program can work as a framework to discuss clinical rating scales for clinical outcome measures between drug developers and a regulatory agency.

PFDD[2)], launched in 2013, is a program that aims to more systematically gather patients' perspective on the condition and available therapies to treat their condition. PFDD has held more than 20 meetings, and each

focused on a specific disease area such as Autism and Parkinson Disease. Patients and FDA discuss needs and issues in drug developments with participants from Academia, etc. This program can work as a framework to incorporate patients' perspective into a clinical trial design or clinical rating scales.

Clinical rating scales is an important area in CDISC standards, international standards for clinical trials. CDISC addresses clinical rating scales in a "Questionnaire, Ratings and Scales (QRS)" [3] document, separated from other documents for data standards. Sometimes, global clinical trials require the development of Japanese version of clinical rating scales based on the English version. This process can be essential to take part in global clinical trials from Japan. Keeping up with COA Qualification Program and PFDD at FDA is advantageous.

1) Clinical Outcome Assessment (COA) Qualification Program
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284077.htm
2) Patient-Focused Drug Development (PFDD)
http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm368342.htm
3) CDISC Questionnaires, Ratings and Scales (QRS)
http://www.cdisc.org/foundational/qrs

Dr. Ken Sakushima
Office of Strategic Programs, U.S. FDA in the U.S.A.

